Literature DB >> 2888876

Mechanisms mediating the positive inotropic and chronotropic changes induced by dopexamine in the anesthetized dog.

A S Bass1, J D Kohli, N Lubbers, L I Goldberg.   

Abstract

Mechanisms contributing to the increments in heart rate (HR) and cardiac contractile force (CCF) produced by dopexamine (DPX) were studied in anesthetized dogs. Intravenous infusions of DPX (4.0 micrograms/kg/min) produced increments in HR, CCF and renal blood flow and decrements in mean arterial pressure (MAP). The sequential administration of atenolol (0.5 mg/kg i.v.) administered at a dose selective for beta-1 adrenoceptors, propranolol (2.5 mg/kg i.v.) and the DA1 dopamine receptor antagonist, SCH 23390 (10 micrograms/kg i.v.) blocked the DPX-induced changes in HR, CCF, MAP and renal blood flow, respectively. After ganglionic blockade, the increments in HR and CCF produced by DPX (4.0 and 16.0 micrograms/kg i.v.) were reduced 90 and 76%, respectively, with little or no change in its hypotensive effect. In separate dogs, administration of the beta-2 adrenoceptor agonist salbutamol (0.55 microgram/kg i.v.) produced a comparable decrement in MAP but smaller increments in HR and CCF than produced by DPX (16.0 micrograms/kg i.v.). DPX (64 micrograms/kg i.v.) also produced greater increments in HR during cardioaccelerator nerve stimulation (1 Hz, 0.5 msec, supramaximal voltage) than before nerve stimulation. Therefore, we tested the effect of DPX (1.0, 4.0 and 8.0 micrograms/kg/min i.v.) on the increments in HR, CCF and MAP produced by norepinephrine (0.25 microgram/kg i.v.) and the indirect acting sympathomimetic amine, tyramine (60 micrograms/kg i.v.). DPX potentiated the increments in HR, CCF and MAP produced by norepinephrine and suppressed those produced by tyramine. Thus, the positive inotropic and chronotropic effects of DPX in the intact dog are due primarily to baroreceptor-mediated stimulation and inhibition of neuronal uptake of norepinephrine.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2888876

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  New dopamine receptor agonists in heart failure and hypertension. Implications for future therapy.

Authors:  P T Horn; M B Murphy
Journal:  Drugs       Date:  1990-10       Impact factor: 9.546

Review 2.  Use of inotropes and vasopressor agents in critically ill patients.

Authors:  Mansoor N Bangash; Ming-Li Kong; Rupert M Pearse
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  Inhibition of 3H-noradrenaline accumulation by dopexamine hydrochloride in the isolated aorta of the rabbit.

Authors:  O A Nedergaard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

Review 4.  Inotropic support of the critically ill patient. A review of the agents.

Authors:  P J Kulka; M Tryba
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Dopexamine maintains mesenteric blood flow during systemic hypoxemia in the neonatal piglet.

Authors:  T V Thomas; T P Mace; E U Choe; L M Flint; J J Ferrara
Journal:  J Gastrointest Surg       Date:  1997 Jul-Aug       Impact factor: 3.452

6.  Presynaptic effects of dopexamine hydrochloride in the canine kidney.

Authors:  A S Bass
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-01       Impact factor: 3.000

7.  Cardiovascular actions of dopexamine in anaesthetized and conscious dogs.

Authors:  R Einstein; N Abdul-Hussein; T W Wong; D H Chang; R Matthews; D P Richardson
Journal:  Br J Pharmacol       Date:  1994-01       Impact factor: 8.739

Review 8.  Dopexamine hydrochloride. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in acute cardiac insufficiency.

Authors:  A Fitton; P Benfield
Journal:  Drugs       Date:  1990-02       Impact factor: 9.546

9.  FPL 63012AR: a potent D1-receptor agonist.

Authors:  G W Smith; J B Farmer; F Ince; K Matu; P D Mitchell; I Naya; B Springthorpe
Journal:  Br J Pharmacol       Date:  1990-06       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.